Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS Kroger NHematology Am Soc Hematol Educ Program 2008[]; ä (ä): 60-7Allogeneic stem cell transplantation can cure patients with myelodysplastic syndromes. However, more than 50% of the patients who underwent allogeneic stem cell transplantation have failed to benefit from this treatment approach either due to treatment-related mortality or to relapse. The introduction of toxicity or dose-reduced conditioning has significantly reduced the treatment-related mortality but did not affect the risk of relapse. New effective drugs, such as hypomethylating agents, histone-deacetylase inhibitors or lenalidomide, can be used alone or in combination to improve the pretransplant remission status before allogeneic stem cell transplantation or after transplantation to prevent relapse as maintenance or consolidation therapy. This review will focus on these new possibilities and give some perspectives as to how the results of allogeneic stem cell transplantation can be further improved.|*Epigenesis, Genetic[MESH]|*Stem Cell Transplantation[MESH]|Busulfan/therapeutic use[MESH]|Combined Modality Therapy[MESH]|Cyclophosphamide/therapeutic use[MESH]|Disease Progression[MESH]|Drug Therapy, Combination[MESH]|Enzyme Inhibitors/therapeutic use[MESH]|Histone Deacetylase Inhibitors[MESH]|Humans[MESH]|Leukemia, Myeloid/etiology[MESH]|Myelodysplastic Syndromes/drug therapy/*genetics/mortality/*surgery[MESH]|Recurrence[MESH]|Risk Factors[MESH]|Siblings[MESH]|Tissue Donors[MESH]|Treatment Outcome[MESH]|Whole-Body Irradiation[MESH] |